Cargando…

Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical Practice

Detalles Bibliográficos
Autores principales:	Delforge, Michel, Vekemans, Marie-Christiane, Depaus, Julien, Meuleman, Nathalie, Van de Velde, Ann, Vande Broek, Isabelle, Vandervennet, Sophie, Van Hoorenbeeck, Sandra, Moorkens, Evelien, Strens, Danielle, Diels, Joris, Ghilotti, Francesca, Haefliger, Benjamin, Dalhuisen, Sander, Deraedt, William, Anguille, Sébastien
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722575/ https://www.ncbi.nlm.nih.gov/pubmed/36479545 http://dx.doi.org/10.1097/HS9.0000000000000813

Ejemplares similares

P12: TREATMENTS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: RETROSPECTIVE CHART REVIEW OF REAL-WORLD OUTCOMES FOR STANDARD OF CARE
por: Vekemans, M-C, et al.
Publicado: (2022)

Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies
por: Cohen, Adam D., et al.
Publicado: (2022)

Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE‐1 (phase 2) Japanese cohort
por: Ri, Masaki, et al.
Publicado: (2022)

P971: ADJUSTED COMPARISON OF PATIENT REPORTED OUTCOMES FROM CARTITUDE-1 AND LOCOMMOTION COMPARING CILTACABTAGENE AUTOLEUCEL VERSUS REAL WORLD CLINICAL PRACTICE IN TRIPLE-CLASS EXPOSED MULTIPLE MYELOMA
por: Weisel, K., et al.
Publicado: (2022)

P904: CILTACABTAGENE AUTOLEUCEL VS TREATMENTS FROM REAL-WORLD CLINICAL PRACTICE FOR TRIPLE CLASS EXPOSED PATIENTS WITH MULTIPLE MYELOMA: ADJUSTED COMPARISONS BASED ON CARTITUDE-1 AND THE EMMY FRENCH COHORT
por: Decaux, O., et al.
Publicado: (2022)

P922: ADJUSTED COMPARISONS OF CILTACABTAGENE AUTOLEUCEL WITH THERAPIES FROM REAL-WORLD CLINICAL PRACTICE: TWO-YEAR FOLLOW-UP ANALYSES FROM CARTITUDE-1 AND THE PROSPECTIVE LOCOMMOTION STUDY
por: Mateos, Maria-Victoria, et al.
Publicado: (2023)

Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE‐1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma
por: Martin, Thomas, et al.
Publicado: (2021)

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
por: Martin, Thomas, et al.
Publicado: (2023)

Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician’s Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
por: Weisel, Katja, et al.
Publicado: (2021)

S202: CARTITUDE-1 FINAL RESULTS: PHASE 1B/2 STUDY OF CILTACABTAGENE AUTOLEUCEL IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Munshi, Nikhil, et al.
Publicado: (2023)

B07: SAFETY AND EFFICACY OF CILTACABTAGENE AUTOLEUCEL, A CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY DIRECTED AGAINST B-CELL MATURATION ANTIGEN IN PATIENTS WITH MULTIPLE MYELOMA AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 RESULTS
por: van de Donk, NWCJ, et al.
Publicado: (2022)

P959: CILTACABTAGENE AUTOLEUCEL IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY: CARTITUDE-2 BIOLOGICAL CORRELATIVE ANALYSES AND UPDATED CLINICAL DATA
por: Hillengass, J., et al.
Publicado: (2022)

P23 EMAGINE/CARTITUDE-6: A RANDOMIZED PHASE 3 STUDY OF DVRD FOLLOWED BY CILTACABTAGENE AUTOLEUCEL VERSUS DVRD FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA
por: Broijl, A., et al.
Publicado: (2023)

B09 CARTITUDE-2 COHORT B 18-MONTH FOLLOW-UP: CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY
por: Zweegman, S., et al.
Publicado: (2023)

P08: CARTITUDE-2 UPDATE: CILTACABTAGENE AUTOLEUCEL, A B-CELL MATURATION ANTIGEN–DIRECTED CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY, IN LENALIDOMIDE-REFRACTORY PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA AFTER 1-3 PRIOR LINES OF THERAPY
por: Einsele, H, et al.
Publicado: (2022)

Population‐based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma
por: Wu, Liviawati S., et al.
Publicado: (2022)

P961: CILTACABTAGENE AUTOLEUCEL, A BCMA-DIRECTED CAR-T CELL THERAPY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: 2-YEAR POST LPI RESULTS FROM THE PHASE 1B/2 CARTITUDE-1 STUDY
por: Lin, Y., et al.
Publicado: (2022)

Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
por: Chekol Abebe, Endeshaw, et al.
Publicado: (2022)

Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry
por: Merz, Maximilian, et al.
Publicado: (2021)

P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON-CELLULAR ANTI-B-CELL MATURATION ANTIGEN (BCMA) IMMUNOTHERAPY
por: van de Donk, N., et al.
Publicado: (2023)

B05: RESULTS FROM A META-ANALYSIS OF CILTACABTAGENE AUTOLEUCEL COMPARED TO PHYSICIAN’S CHOICE OF TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
por: Gay, F, et al.
Publicado: (2022)

Adjusted comparison of outcomes between patients from CARTITUDE-1 versus multiple myeloma patients with prior exposure to proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibody from the prospective, multinational LocoMMotion study of real-world clinical practice
por: Mateos, Maria-Victoria, et al.
Publicado: (2022)

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma
por: Iacoboni, Gloria, et al.
Publicado: (2022)

Repeated Infusions of Brexucabtagene-autoleucel in Relapsed/Refractory Mantle Cell Lymphoma
por: Aydilek, Enver, et al.
Publicado: (2023)

Rare Heterozygous PCSK1 Variants in Human Obesity: The Contribution of the p.Y181H Variant and a Literature Review
por: Van Dijck, Evelien, et al.
Publicado: (2022)

Safety and efficacy of letetresgene autoleucel alone or with pembrolizumab for relapsed/refractory multiple myeloma
por: Nishihori, Taiga, et al.
Publicado: (2022)

Brexucabtagene autoleucel for mantle cell lymphoma, B-cell precursor acute lymphoblastic leukaemia
Publicado: (2023)

P935: REAL WORLD COMPARATIVE ANALYSIS OF THE EFFICACY OF TECLISTAMAB VERSUS CURRENT TREATMENTS IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE LOCOMOTION STUDY
por: Einsele, H., et al.
Publicado: (2022)

P1391: VARNIMCABTAGENE AUTOLEUCEL (VAR-CEL) IN RELAPSED/ REFRACTORY CD19+ NON-HODGKIN LYMPHOMA
por: Martinez-Cibrian, Nuria, et al.
Publicado: (2023)

Copy number variant analysis and expression profiling of the olfactory receptor-rich 11q11 region in obesity predisposition
por: Diels, Sara, et al.
Publicado: (2020)

S100: FIRST PHASE 3 RESULTS FROM CARTITUDE-4: CILTA-CEL VERSUS STANDARD OF CARE (PVD OR DPD) IN LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA
por: Einsele, Hermann, et al.
Publicado: (2023)

An overview of patents on therapeutic monoclonal antibodies in Europe: are they a hurdle to biosimilar market entry?
por: Moorkens, Evelien, et al.
Publicado: (2020)

Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma
por: Moreau, Philippe, et al.
Publicado: (2023)

Comparative Efficacy of Ibrutinib Versus Obinutuzumab + Chlorambucil in First-Line Treatment of Chronic Lymphocytic Leukemia: A Matching-Adjusted Indirect Comparison
por: Van Sanden, Suzy, et al.
Publicado: (2017)

Relmacabtagene autoleucel (relma‐cel) CD19 CAR‐T therapy for adults with heavily pretreated relapsed/refractory large B‐cell lymphoma in China
por: Ying, Zhitao, et al.
Publicado: (2020)

P1155: BREXUCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN ROUTINE PRACTICE: UPDATED REPORT FROM THE US LYMPHOMA CAR T CONSORTIUM
por: Wang, Y., et al.
Publicado: (2022)

Economic evaluation of biosimilars for reimbursement purposes – what, when, how?
por: Moorkens, Evelien, et al.
Publicado: (2020)

An Indirect Comparison of Changes in the Impact of Weight on Quality of Life Among Subjects with Type 2 Diabetes Treated with Antihyperglycemic Agents in Dual Therapy with Metformin
por: Traina, Shana B., et al.
Publicado: (2017)

Dendritic Cell-Based and Other Vaccination Strategies for Pediatric Cancer
por: de Bruijn, Sévérine, et al.
Publicado: (2019)

S312: IS BREXUCABTAGENE AUTOLEUCEL A COST-EFFECTIVE TREATMENT FOR REFRACTORY/RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA? A PHARMACOECONOMIC ANALYSIS IN THE PERSPECTIVE OF THE PUBLIC HEALTHCARE SYSTEM.
por: Marchetti, Monia
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2asn3gb5ontpfb970m811jitev